不可切除神经内分泌肿瘤患者接受177Lu DOTATATE(LuTate)治疗时肿瘤剂量学与缓解及总生存的关系
回顾性分析90例胃肠胰神经内分泌肿瘤患者接受LuTate治疗,第1周期可测量病灶辐射剂量与局部缓解相关(每50 Gy比值比1.5,95%CI 1.1-2.0,P=0.002),但基线及变化MITVSSR均与总生存无显著关联,5年总生存68%。
要点
- 第1周期可测量病灶辐射剂量与局部缓解相关,校正肿瘤分级和放疗增敏化疗后每50 Gy比值比1.5(95%CI 1.1-2.0,P=0.002)。
- MITVSSR中位变化-63%(四分位距-84至-29),与最摄取病灶辐射剂量无相关性(每10 Gy 5.6,95%CI -1.6至12.8,P=0.133)。
- 基线MITVSSR及变化均与总生存无显著关联,放疗增敏化疗与总生存相关(95%CI 0.2-0.8,P=0.012)。
核心结论
- PRRT期间肿瘤辐射剂量可预测影像学缓解,但与生存无关。
- 生存结局可能与其他生物学因素有关。
- 无证据表明MITVSSR变化与总生存相关,但需更大规模研究。
研究设计与样本
- 回顾性分析2010年7月至2019年1月接受LuTate治疗的胃肠胰神经内分泌肿瘤患者,次日行定量SPECT/CT。
- 共90例患者,中位4个PRRT周期(范围2-5周期),平均累积活度27.4 GBq,平均每周期7.6 GBq。
- 采用基于人群的药代动力学模型进行单时间点病灶剂量学,PRRT后3个月测量MITVSSR和RECIST 1.1。
主要发现
- 68%患者至少一个周期接受放疗增敏化疗。
- RECIST 1.1部分缓解24%,疾病稳定70%,疾病进展7%。
- 第1周期可测量病灶辐射剂量与局部缓解相关,校正肿瘤分级和放疗增敏化疗后每50 Gy比值比1.5(95%CI 1.1-2.0,P=0.002)。
- MITVSSR中位变化-63%(四分位距-84至-29),与最摄取病灶辐射剂量在单变量或多变量分析中均无相关性(每10 Gy 5.6,95%CI -1.6至12.8,P=0.133)。
- 5年总生存68%(95%CI 56-78%);校正肿瘤分级和放疗增敏化疗后,基线MITVSSR(风险比1.1,95%CI 1.0-1.2,P=0.128)及基线MITVSSR变化(风险比1.0,95%CI 1.0-1.1,P=0.223)均与总生存无显著关联,放疗增敏化疗与总生存相关(95%CI 0.2-0.8,P=0.012)。
关键数值与推荐
- 第1周期可测量病灶辐射剂量每增加50 Gy,局部缓解比值比1.5(95%CI 1.1-2.0,P=0.002),校正肿瘤分级和放疗增敏化疗。
- MITVSSR中位变化-63%(四分位距-84至-29)。
- 5年总生存率68%(95%CI 56-78%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需更大规模研究以评估MITVSSR变化与总生存的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response by 68 Ga DOTATATE (GaTate) PET/CT molecular imaging tumour volume of SSR (MITVSSR) change and RECIST 1.1, and overall survival (OS). METHODS: Patients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT/CT (Q-SPECT/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. Single time-point (STP) lesional dosimetry was performed for each cycle using population-based pharmacokinetic modelling. MITVSSR and RECIST 1.1 were measured at 3-months post PRRT. RESULTS: Median of 4 PRRT cycles were administered to 90 patients (range 2-5 cycles; mean 27.4 GBq cumulative activity; mean 7.6 GBq per cycle). 68% received at least one cycle with radiosensitising chemotherapy (RSC). RECIST 1.1 partial response was 24%, with 70% stable and 7% progressive disease. Cycle 1 radiation dose in measurable lesions was associated with local response (odds ratio 1.5 per 50 Gy [95% CI: 1.1-2.0], p = 0.002) when adjusted by tumour grade and RSC. Median change in MITVSSR was -63% (interquartile range -84 to -29), with no correlation with radiation dose to the most avid lesion on univariable or multivariant analyses (5.6 per 10 Gy [95% CI: -1.6, 12.8], p = 0.133). OS at 5-years was 68% (95% CI: 56-78%). Neither baseline MITVSSR (hazard ratio 1.1 [95% CI: 1.0, 1.2], p = 0.128) nor change in baseline MITVSSR (hazard ratio 1.0 [95% CI: 1.0, 1.1], p = 0.223) were associated with OS when adjusted by tumour grade and RSC but RSC was (95% CI: 0.2, 0.8, p = 0.012). CONCLUSION: Radiation dose to tumour during PRRT was predictive of radiologic response but not survival. Survival outcomes may relate to other biological factors. There was no evidence that MITVSSR change was associated with OS, but a larger study is needed.
引用
- Alipour R, Jackson P, Bressel M, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023. PMID: 37184682. doi:10.1007/s00259-023-06257-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。